BrECADD Is Non-Inferior to eBEACOPP in Patients with Advanced Stage Classical Hodgkin Lymphoma: Efficacy Results of the GHSG Phase III HD21 Trial - Borchmann, P; Moccia, AA; Greil, R (Hematological Oncology, 2023)
et al.